<DOC>
	<DOCNO>NCT00866788</DOCNO>
	<brief_summary>The study Phase II , dose-ranging , multicenter , randomize , double-blind , placebo-controlled , parallel-group study efficacy safety single subcutaneously administer omalizumab dose add-on therapy treatment adolescent adult patient 12-75 year old diagnose CIU remain symptomatic despite treatment therapeutic dos H1 antihistamine . The study enroll approximately 76 patient approximately 45 study center United States Germany .</brief_summary>
	<brief_title>A Study Xolair ( Omalizumab ) Patients With Chronic Idiopathic Urticaria ( CIU ) Who Remain Symptomatic With Antihistamine Treatment ( H1 )</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<criteria>CIU diagnosis &gt; 3 month ( history ) No underlie etiology clearly define urticaria ( main manifestation physical urticaria ) Pregnant , breastfeeding , woman take contraception Patients &lt; 40kg Treatment investigational agent within 30 day screen Recent history drug alcohol abuse Atopic dermatitis skin disease associate pruritus Clinically relevant major systemic disease ( make interpretation study result difficult ) Previously treat omalizumab ( &lt; 12 month since last injection ) Patients may take treatment period take within past 3 month follow medications/treatments : regular ( daily/every day ) hydroxychloroquine , methotrexate , cyclosporine , cyclophosphamide , IVIG , plasmapheresis Patients may take doxepin within past 6 week regular ( daily/every day ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Xolair</keyword>
	<keyword>CIU</keyword>
</DOC>